NOVELTY – 4-Anilinequinazoline derivatives are new. USE – For treating lesions caused by myocardiac ischemia in a patient with acute coronary syndrome (myocardium infract and unstable angina) and in a heart-donating patient to preserve the tissue during the period before implantation in the receptor; lesions caused by hepatic ischemia in liver-donating patient; lesions caused by renal ischemia in a kidney-donating patient; lesions caused by cerebral ischemia in a patient in danger of developing cerebral ischemia; lesions caused by chronic inflammatory disease in a patient of rheumatoid arthritis or chronic intestinal inflammatory disease; lesions caused by inflammatory disease in a patient of systemic erythematous lupus; pain caused by cancer, degenerative and chronic inflammatory disease; and also useful for treating or preventing re-stenosis of coronary, renal and iliac arteries in a patient in danger of developing re-stenosis after angioplasty; and atherosclerosis in a patient with an already established atherosclerosis or to prevent its develoment (claimed). ADVANTAGE – The compounds are effective in protection of the myocardium, brain, kidneys and liver from the effect of ischemia/reperfusion. DETAILED DESCRIPTION – 4-Anilinequinazoline derivatives of formula (I) are new. R1 and R2=alkoxy (preferably OCH3); and R3=H, halo, OCH3, CH3, -C(O)CH3, -N(CH3)2 or NO2. R1 – R3 Occupy 3 or 4 position of N-phenyl group, generating meta and para-substituted quinazolinic compounds.
B02 (Fused ring heterocyclics.)